Press releases

26th March 2024

STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024

Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024

22nd February 2024

STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress

Data demonstrates pharmacological inhibition of METTL1 inhibits tumour growth and reduces tRNA methylation and stability of tRNAs

8th December 2023

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference

Data demonstrates METTL1 inhibition in vitro at low nanomolar concentrations while displaying high selectivity over other RNA and protein methyltransferases. Data provides the first proof-of-concept that pharmacological inhibition of a tRNA methyltransferase affects tumour growth in vitro and in animal models.

1st November 2023

STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer

STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce the appointment of Marguerite Hutchinson, J.D., as Chief Business Officer.

17th October 2023

STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

STORM’s first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase. STC-15 reshapes the tumour microenvironment and activates anti-tumour immunity.